D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment

Expert Opinion on Biological Therapy

Volumn 14, Issue 3, 2014, Pages 283-286

  Yalcin, Arzu Didem ^a   Celik, Betul ^b   Gumuslu, Saadet ^c  

^a ACADEMIA SINICA   (Taiwan)

^b MAYO CLINIC   (United States)

^c AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Anti immunoglobulin E; Antithrombin III; Chronic urticaria; D dimer; Factor V Leiden and prothrombin G20210A mutation; Omalizumab; Protein C; Severe persistent allergic asthma

Indexed keywords

ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; MONOCLONAL ANTIBODY; OMALIZUMAB;

ADULT; ASTHMA; BLOOD; CHRONIC DISEASE; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY; MALE; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URTICARIA;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URTICARIA;

EID: 84894113358     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.875525     Document Type: Article

References (17)

1. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000;18:157-62
2. Yalcin AD, Cilli A, Bisgin A,et al. Omalizumab is effective in treating severe asthma in patients with severe cadiovascular complications and its effects on sCD200, d-dimer, CXCL8 and IL-1beta levels. Expert Opin Biol Ther 2013;13(9):1335-41
3. Criado PR, Antinori LC, Maruta CW,et al. Evaluation of D-dimer serum levels among patients with chronic urticaria, psoriasis and urticarial vasculitis. An Bras Dermatol 2013;88(3):355-60
4. Triwongwaranat D, Kulthanan K, Chularojanamontri L,et al. Correlation between plasma D-dimer levels and the severity of patients with chronic urticaria. Asian Pac Allergy 2013;3:100-5
5. Boer JD, Majoor CJ, Veer C,et al. Asthma and coagulation. Blood 2012;119:3236-44
6. Danese S, Vetrano S, Zhang L,et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010;115(6):1121-30
7. Hataji O, Taguchi O, Gabazza EC,et al. Activation of protein C pathway in the airways. Lung 2002;180(1):47-59
8. Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention. 2012. Available from: www.ginasthma.org
9. Zuberbier T, Asero R, Bindslev-Jensen C,et al. Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA (2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427-43
10. Ritis K, Doumas M, Mastellos D,et al. A novel C5a receptor-tissue factor crosstalk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006;177(7):4794-802
11. Heimall J, Freeman A, Holland SM. Pathogenesis of hyper IgE syndrome. Clin Rev Allergy Immunol 2010;38(1):32-8
12. Bard S, Paravisini A, Aviles-Izquierdo JA,et al. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol 2008;144(12):1662-3
13. Belloni B, Ziai M, Lim A,et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:1223-5
14. Niven AS, Argyros G. Alternate treatments in asthma. Chest 2003;123(4):1254-65
15. Yalcin AD, Gorczynski RM, Parlak GE,et al. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin Lab 2012;58(1-2):89-96
16. Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL10, TGF-beta and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm 2012;2012:720976
17. Yalcin AD, Bisgin A, Genc GE,et al. Evaluation of homocysteine, eosinophil cationic peptide, 25(OH) vitamin D, pro-inflammatory IL-1beta and immune modulator OX-2 levels in moderate allergic asthma patients: association with biological treatment (Omalizumab; Anti-IgE) & disease activity. Immunopharmacol Immunotoxicol 2013; Accepted